TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
BIOA

BioAge Labs, Inc

Healthcare · Drug Manufacturers - Specialty & Generic · —

8.10$ -0.4% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns BioAge Labs, Inc (BIOA)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 85.4% of the shares are freely tradable; institutional investors hold 85.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 85.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 2.4%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 85.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 6.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 46Mio.

Largest Shareholders

Institutions

Institutions BIOA
Name Stake (%) Shares Change (%) Date
Cormorant Asset Management, LLC 6.30 2,890,605 +41.7 03/31/2026
Sofinnova Ventures 5.00 2,293,788 +0.0 03/31/2026
BlackRock Inc 4.94 2,267,756 +48.5 03/31/2026
HHG PLC 4.56 2,094,270 +411.8 03/31/2026
Octagon Capital Advisors LP 3.81 1,748,000 +0.0 06/30/2026
MPM Oncology Impact Management LP 3.63 1,667,661 +0.0 06/30/2026
RA Capital Management, LLC 3.60 1,650,648 +0.0 03/31/2026
Vanguard Capital Management, LLC 2.95 1,354,906 +0.0 03/31/2026
Balyasny Asset Management LLC 2.89 1,327,545 +0.0 03/31/2026
BRAIDWELL LP 2.62 1,200,587 +0.0 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?